

Publikationsliste Helen Kovari, 27.07.2018

1. Originalarbeiten

1. Laut K, Shepherd L, Radoi R, Karpov I, Parczewski M, Mussini C, Maltez F, Losso M, Chkhartishvili N, Elinav H, **Kovari H**, Blaxhult A, Zangerle R, Trofimova T, Inglot M, Zilmer K, Kuzovatova E, Staub T, Raben D, Lundgren J, Mocroft A, Kirk O, On Behalf Of The EuroSIDA Study Group. Persistent disparities in antiretroviral treatment (ART) coverage and virological suppression across Europe, 2004 to 2015. *Euro Surveill.* 2018 May; 23(21).
2. Reinschmidt S, Turk T, Tarr PE, Kouyos RD, Hauser C, Schmid P, Weber R, Kaufmann PA, Buechel RR, **Kovari H**; Swiss HIV Cohort Study. Incidental findings on coronary computed tomography angiography in HIV-positive and HIV-negative persons. *Open Forum Infect Dis* 2018; 5(5): ofy084.
3. Marzel A, Kouyos RD, Reinschmidt S, Balzer K, Garon F, Spitaleri M, Matthes N, Suter P, Weber R, Staehelin C, Lecompte TD, Tarr PE, **Kovari H**; Swiss HIV Cohort Study. Dietary Patterns and Physical Activity Correlate With Total Cholesterol Independently of Lipid-Lowering Drugs and Antiretroviral Therapy in Aging People Living With Human Immunodeficiency Virus. *Open Forum Infect Dis* 2018; 5(4): ofy 067.
4. Tarr PE, Ledergerber B, Calmy A, Doco-Lecompte T, Marzel A, Weber R, Kaufmann PA, Nkoulou R, Buechel RR, **Kovari H**; Swiss HIV Cohort Study. Subclinical coronary artery disease in Swiss HIV-positive and HIV-negative persons. *Eur Heart Journal.* 2018; 39(23): 2147-2154.
5. Hatleberg CI, Ryom L, El-Sadr W, Mocroft A, Reiss P, De Wit S, Dabis F, Pradier C, d'Arminio Monforte A, **Kovari H**, Law M, Lundgren JD, Sabin CA; Data Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group. Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study. *J Int AIDS Soc.* 2018 Mar; 21(3).
6. Béguelin C, Suter A, Bernasconi E, Fehr J, **Kovari H**, Bucher HC, Stoeckle M, Cavassini M, Rougemont M, Schmid P, Wandeler G, Rauch A; Swiss HIV Cohort Study. Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study. *Liver Int.* 2017 Jul 25.
7. Lodi S, Costagliola D, Sabin C, Amo JD, Logan R, Abgrall S, Reiss P, van Sighem A, Jose S, Blanco JR, Hernando V, Bucher HC, **Kovari H**, Segura F, Ambrosioni J, Gogos CA, Pantazis N, Dabis F, Vandenhende MA, Meyer L, Seng R, Gill J, Krentz H, Phillips A, Porter K, Grinsztejn B, Pacheco AG, Muga R, Tate J, Justice A, Hernán MA. Effect of immediate initiation of antiretroviral treatment in HIV-positive individuals aged 50 years or older. *J Acquir Immune Defic Syndr.* 2017; 76(3): 311-318.
8. **Kovari H**, Rauch, A, Kouyos R, Rougemont M, Cavassini M, Schmid P, Stöckle M, Bernasconi E, Weber R, Ledergerber B, and the Swiss HIV Cohort Study. Hepatitis C infection and the risk of non-liver-related morbidity and mortality in HIV-positive persons in the Swiss HIV Cohort Study. *Clin Inf Dis* 2017 Feb 15; 64(4): 490-497.
9. Shilaih M, Marzel A, Braun DL, Scherrer AU, **Kovari H**, Young J, Calmy A, Darling K, Battegay M, Hoffmann M, Bernasconi E, Thurnheer MC, Günthard HF, Kouyos RD; and the Swiss HIV Cohort Study. Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretrovirals. *Medicine (Baltimore).* 2017 Jan; 96(2):e5849.
10. Peters L, Zangerle R, Touloumi G, Dauchy F-A, van der Valk M,, Gert Fätkenheuer G, Noguera-Julian A, Gonzales J, Dabis F, Castagna A, d'Arminio Monforte A, Torti C, Mussini C, Ceescat J, **Kovari H**, de Wit S, Raben D, Chene G and Cozzi-Lepri A. COHERE (2017). Is response to anti-hepatitis C virus treatment predictive of mortality in hepatitis C virus/HIV-positive patients? *AIDS* 2017, 31(5):661-668.

11. Wandeler G, Mulenga L, Vinikoor MJ, **Kovari H**, Battegay M, Calmy A, Cavassini M, Bernasconi E, Schmid P, Bolton-Moore C, Sinkala E, Chi BH, Egger M, Rauch A; for IeDEA-Southern Africa and the Swiss HIV Cohort Study. Liver fibrosis in treatment-naïve HIV-infected and HIV/HBV co-infected patients: Zambia and Switzerland compared. *Int J Infect Dis*. 2016 Oct; 51: 97-102.
12. Junier T, Rotger M, Biver E, Ledergerber B, Barcelò C, Bartha I, **Kovari H**, Rickenbach M, Cavassini M, Weber R, Vernazza P, Bernasconi E, Furrer H, Battegay M, Telenti A, Fellay J, Tarr PE, and the Swiss HIV Cohort Study. Contribution of genetic background and clinical risk factors to low-trauma fractures in HIV-positive persons: The Swiss HIV Cohort Study. *Open Forum Infect Dis* 2016; 3: ofy101.
13. Shilaih M, Marzel A, Scherrer AU, Braun D, **Kovari H**, Calmy A, Darling K, Battegay M, Hoffmann M, Bernasconi E, Rauch A, Günthard HF, Kouyos R, and The Swiss HIV Cohort Study. Dually Active HIV/HBV Antiretrovirals Protect Against Incident Hepatitis B Infections: Potential for Prophylaxis. *J Infect Dis* 2016; 214: 599-606.
14. Niedrig D, Maechler S, Hoppe L, Corti N, **Kovari H**, Russmann S. Drug safety of macrolide and quinolone antibiotics in a tertiary care hospital: administration of interacting co-medication and QT prolongation. *Eur J Clin Pharmacol* 2016; 72: 859-67.
15. **Kovari H**, Sabin CA, Ledergerber B, Ryom L, Reiss P, Law M, Pradier C, Dabis F, d'Arminio Monforte A, Smith C, de Wit S, Kirk O, Lundgren JD, Weber R. Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in HIV-Monoinfected Persons: The D:A:D Study Group. *Open Forum Infect Dis* 2016; 3: ofw009.
16. Ryom L, Lundgren JD, De Wit S, **Kovari H**, Reiss P, Law M, El-Sadr W, Monforte AD, Mocroft A, Smith C, Fontas E, Dabis F, Phillips A, Sabin C; D:A:D Study Group. Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. *AIDS* 2016; 30:1731-43.
17. **Kovari H**, Russmann S, Ledergerber B, Müller D, Rotger M, Velli P, Cavassini M, Ambrosioni J, Bregenzer A, Stöckle M, Bernasconi E, Rauch A, Speck RF; Swiss HIV Cohort Study. Ribavirin concentrations do not predict sustained virological response in HIV/HCV-coinfected patients treated with ribavirin and pegylated interferon in the Swiss HIV Cohort Study. *PLoS One* 2015; 10: e0133879.
18. Schaerer V, Haubitz S, **Kovari H**, Ledergerber B, Ambrosioni J, Cavassini M, Stöckle M, Schmid P, Decosterd L, Aouri M, Böni J, Günthard HF, Furrer H, Metzner KJ, Fehr J, Rauch A; Swiss HIV Cohort Study. Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake. *HIV Med* 2015; 16: 599-607
19. **Kovari H**, Ledergerber B, Cavassini M, Ambrosioni J, Bregenzer A, Stöckle M, Bernasconi E, Kouyos R, Weber R, Rauch A; Swiss HIV Cohort Study. High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV Cohort Study between 2001 and 2013. *J Hepatol*. 2015; 63: 573-580.
20. Kouyos RD, Rauch A, Braun DL, Yang WL, Böni J, Yerly S, Klimkait T, Aubert V, Shah C, **Kovari H**, Calmy A, Cavassini M, Battegay M, Vernazza PL, Bernasconi E, Ledergerber B, Günthard HF; Swiss HIV Cohort Study. Higher risk of incident hepatitis C virus coinfection among men who have sex with men, in whom the HIV genetic bottleneck at transmission was wide. *J Infect Dis* 2014; 210:1555-1561.
21. Kouyos RD, Rauch A, Böni J, Yerly S, Shah C, Aubert V, Klimkait T, **Kovari H**, Calmy A, Cavassini M, Battegay M, Vernazza PL, Bernasconi E, Ledergerber B, Günthard HF; Swiss HIV Cohort Study. Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV. *Int J Epidemiol* 2014; 43:887-896.
22. **Kovari H**, de Melo Oliveira MD, Hauser P, Lächli S, Meyer J, Weber R, Zbinden R. Decreased susceptibility of *Neisseria gonorrhoeae* isolates from Switzerland to cefixime and ceftriaxone: antimicrobial susceptibility data from 1990 and 2000 to 2012. *BMC Infect Dis* 2013; 13:603.

23. Rohrbach J, Stickel F, Schmid P, Thormann W, **Kovari H**, Scherrer A, Günthard HF, Vuichard D, Cavassini M, Ambrosioni J, Bernasconi E, Furrer H, Rauch A; the Swiss HIV Cohort Study. Changes in biomarkers of liver disease during successful combination antiretroviral therapy in HIV/HCV-coinfected individuals. *Antivir Ther* 2014; 19:149-159.
24. Wandeler G, Gsponer T, Bihl F, Bernasconi E, Cavassini M, **Kovari H**, Schmid P, Battegay M, Calmy A, Egger M, Furrer H, Rauch A; the Swiss HIV Cohort Study. Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV Cohort Study. *J Infect Dis* 2013; 208:1454-1458.
25. Bertisch B, Franceschi S, Lise M, Vernazza P, Keiser O, Schöni-Affolter F, Bouchardy C, Dehler S, Levi F, Jundt G, Ess S, Pawlita M, **Kovari H**, Wandeler G, Calmy A, Cavassini M, Stöckle M, Clifford G; Swiss HIV Cohort Study. Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study. *Am J Epidemiol* 2013; 178:877-884.
26. Sabin CA, Ryom L, **Kovari H**, Kirk O, de Wit S, Law M, Reiss P, Dabis F, Pradier C, El Sadr W, Monforte AD, Kamara D, Phillips AN, Lundgren JD. Association between ALT level and the rate of cardio/cerebrovascular events in HIV-positive individuals: The D:A:D Study. *J Acquir Immune Defic Syndr* 2013; 63:456-463.
27. **Kovari H**, Sabin CA, Ledergerber B, Ryom L, Worm SW, Smith C, Phillips A, Reiss P, Fontas E, Petoumenos K, De Wit S, Morlat P, Lundgren JD, Weber R. Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of HBV or HCV co-infection. The D:A:D Study. *Clin Infect Dis* 2013; 56:870-879.
28. Savaria F, Zbinden R, Wüst J, Burnens A, Ledergerber B, Weber R, **Kovari H**. Antimicrobial resistance among *E. coli* in urinary specimens: prevalence data from three laboratories in Zurich between 1985 and 2010. *Praxis* 2012; 101:573-579.
29. Simmons R, Sharp C, McClure CP, Rohrbach J, **Kovari H**, Frangou E, Simmonds P, Irving W, Rauch A, Bowness P, Klenerman P; Swiss HIV Cohort Study. Parvovirus 4 infection and clinical outcome in high-risk populations. *J Infect Dis* 2012; 205:1816-1820.
30. Pillai SK, Abdel-Mohsen M, Guatelli J, Skasko M, Monto A, Fujimoto K, Yuki S, Greene WC, **Kovari H**, Rauch A, Fellay J, Battegay M, Hirschel B, Witteck A, Bernasconi E, Ledergerber B, Günthard HF, Wong JK. Role of retroviral restriction factors in the interferon- α -mediated suppression of HIV-1 in vivo. *Proc Natl Acad Sci USA* 2012; 109:3035-3040.
31. Kenfak-Foguena A, Schöni-Affolter F, Bürgisser P, Witteck A, Darling KE, **Kovari H**, Kaiser L, Evison JM, Elzi L, Gurter-De La Fuente V, Jost J, Moradpour D, Abravanel F, Izpopet J, Cavassini M; Swiss HIV Cohort Study. Hepatitis E virus seroprevalence and chronic infections in patients with HIV, Switzerland. *Emerg Infect Dis* 2011; 17: 1074-1078.
32. Ortiz M, Poloni ES, Furrer H, **Kovari H**, Martinez R, Arnedo M, Elzi L, Bernasconi E, Vernazza P, Hirschel B, Cavassini M, Ledergerber B, Günthard HF, Telenti A, Tarr PE; Swiss HIV Cohort Study. No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipodystrophy. *J Infect Dis* 2011; 203:620-4. Impact factor: 5.997 (2014)
33. **Kovari H**, Ledergerber B, Battegay M, Rauch A, Hirschel B, Foguena AK, Vernazza P, Bernasconi E, Mueller NJ, Weber R. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis B or C virus co-infection. *Clin Infect Dis* 2010; 50:502-511.
34. Dang T, Jatton-Ogay K, Flepp M, **Kovari H**, Evison JM, Fehr J, Schmid P, Boffi El Amari E, Cavassini M, Odorico M, Tarr PE, Greub G. High prevalence of anorectal chlamydial infection in HIV-infected men who have sex with men in Switzerland. *Clin Infect Dis* 2009; 49:1532-1535.

35. **Kovari H**, Ledergerber B, Peter U, Flepp M, Jost J, Schmid P, Calmy A, Mueller NJ, Muellhaupt B, Weber R; Swiss HIV Cohort Study. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. *Clin Infect Dis* 2009; 49:626-635.
36. Podlekareva D, Mocroft A, Kirk O, Reiss P, Aldins P, Katlama C, **Kovari H**, Stellbrink HJ, D'Arminio Monforte A, Lundgren JD; EuroSIDA Study Group. Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART. *Scand J Infect Dis* 2008; 40:908-913.
37. Latal-Hajnal B, von Siebenthal K, **Kovari H**, Bucher HU, Largo RH. Postnatal growth in VLBW infants: significant association with neurodevelopmental outcome. *J Pediatr* 2003; 143:163-70.

2. Fallbeschreibungen

1. Hugelshofer M, Achermann Y, **Kovari H**, Dent W, Hombach M, Bloemberg G. Meningoencephalitis with subdural empyema caused by toxigenic clostridium perfringens type A. *J Clin Microbiol* 2012; 50:3409-3411.
2. Hofmaenner D, **Kovari H**, Weber A, Weishaupt D, Speck R. Nodular regenerative hyperplasia of the liver associated with didanosine persists for years even after its interruption. *BMJ Case reports* 2011.
3. **Kovari H**, Ebnöther C, Schweiger A, Berther N, Kuster H, Günthard HF. Pulmonary toxoplasmosis, a rare but severe manifestation of a common opportunistic infection in late HIV presenters: report of two cases. *Infection* 2010; 38:141-144.

3. Übersichtsarbeiten

1. Engel T, Raffenberg M, Marzolini C, Cavassini M, **Kovari H**, Hasse B, Tarr PE. HIV and Aging - Perhaps Not as Dramatic as We Feared? *Gerontology* 2018; 15: 1-11.
2. Tarr P, Schmid P, Bernasconi E, Stoeckle M, **Kovari H**. HIV-Infektion. *Schweiz Med Forum* 2015; 15:479-485.
3. Landolt L, **Kovari H**. Das Erythema migrans. *Praxis* 2014; 103:1-8.
4. Hasse B, Bernasconi E, Furrer H, Eyer MM, **Kovari H**. HIV-associated non-AIDS conditions. *Ther Umsch* 2014; 71:483-489.
5. Tarr P, Baumann K, Wallnöfer A, Zimmerli F, Maritz D, Burri U, Egger M, Clerc O, Bernasconi E, **Kovari H**, Senn L. Akute Harnwegsinfektionen, Teil 2: HWI im Spital und Alters- und Pflegeheim. *Schweiz Med Forum* 2013;13:472-475.
6. Tarr P, Baumann K, Wallnöfer A, Zimmerli F, Maritz D, Burri U, Egger M, Clerc O, Bernasconi E, **Kovari H**, Senn L. Akute Harnwegsinfektionen, Teil 1: HWI in der Praxis. *Schweiz Med Forum* 2013;13:467-471.
7. **Kovari H**, Weber R. Influence of Antiretroviral Therapy on Liver Disease. *Curr Opin HIV AIDS* 2011; 6:272-277.

4. Angeleitete Dissertationen

1. Fabrice Savaria. Antibiotikaresistenzen von E.coli in Urinproben: Prävalenzdaten dreier Laboratorien im Raum Zürich von 1985 bis 2010. 2012
2. Alina Kägi. Cystic infections in the Swiss ADPKD-cohorte (ongoing).

5. Andere Publikationen

1. Tarr PE, **Kovari H**. Another statin option in HIV. Lancet HIV 2017.
2. Taegtmeyer AB, Müller V, **Kovari H**, Kullak-Ublick GA, Corti N. Effect of continuous venovenous hemodiafiltration on darunavir and raltegravir exposure after administration via a gastroduodenal tube. AIDS. 2011; 25:1339-1341.
3. **Kovari H**, Ledergerber B, Weber R. Should HIV-infected patients with unexplained chronic liver enzyme elevations be tested for hepatitis E virus? Reply. Clin Infect Dis 2010; 50:1546-1547.
4. **Kovari H**, Ledergerber B, Weber R. Idiopathic noncirrhotic portal hypertension in HIV-infected patients. Reply. Clin Infect Dis 2010; 50:128-129.